Washington, Dec 24 (ANI): People who take painkiller Celebrex and also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke might not be getting enough protection because the former drug keeps the aspirin from doing its job effectively, according to a new study.
In laboratory studies, University of Michigan researchers found that several coxibs, the drug class to which Celebrex belongs, interfere with aspirin's ability to discourage blood clots, if the aspirin is taken in low doses.
Celebrex, also known as celecoxib, is the only coxib currently on the market.
Doctors frequently advise daily low-dose aspirin (81 mg) for patients who have heart conditions, notably a serious form of angina known as unstable angina, or for patients who are at risk of second heart attacks.
Aspirin is well known for its ability to discourage formation of blood clots that can lead to heart attack and stroke.
In addition, arthritis patients who take Celebrex regularly are often put on low-dose aspirin because this is thought to counteract Celebrex's own potential clot-promoting effect.
"There are many people who take low-dose aspirin, perhaps as many as half of men over 50. If they are also prescribed Celebrex for arthritis or other pain, our results suggest that the Celebrex will probably interfere with the aspirin's action," said Dr. William L. Smith, the study's senior author.
"The greatest risk is having people take Celebrex who are taking aspirin for cardiovascular problems that are known to be mitigated by aspirin, including patients with unstable angina or those at risk for a second heart attack," he said.
In unstable angina, small clots form in arteries and interfere with blood flow.
Previous studies of healthy subjects found no ill effect on blood clotting when Celebrex was combined with aspirin at higher doses, specifically a daily "regular" aspirin tablet (324 mg), Smith notes.
So it may be that a higher aspirin dose, or spreading out the time between taking low-dose aspirin and Celebrex, will allow aspirin to be effective.
Aspirin's undesirable effects on the gastrointestinal tract at higher doses when taken long-term would have to be taken into account.
While the effect seen in the study needs to be replicated in studies of low-dose aspirin and Celebrex in people, perhaps in older patients, who have conditions such as rheumatoid arthritis, said Smith.
If the effect holds true in people, it will be important to determine if a balance in dose and/or dose regimens can be found so that aspirin and Celebrex can both be effective.
The results appear online in the Proceedings of the National Academy of Sciences. (ANI)